BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, ...

"We are pleased to be sharing several new analyses relating to aficamten at the upcoming ACC Scientific Session & Expo,” said ...

Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

a Phase 1/2 study in patients with DMD44 (poster presentation) Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1 ...

Presentation: First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, in Adults with MYBPC3 -Associated ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

KLE VK Institute of Dental Sciences hosts 28th Scientific Conference showcasing student excellence in dental care innovations ...

today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held ...

today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14 ...

The Meritus School of Osteopathic Medicine recently hosted its first research and scholarly activity conference, Meritus ...